Proteostasis Therapeutics Inc (NASDAQ:PTI) shares were down 6.3% during trading on Friday . The stock traded as low as $3.37 and last traded at $3.55, approximately 10,819,340 shares traded hands during mid-day trading. An increase of 624% from the average daily volume of 1,494,726 shares. The stock had previously closed at $3.79.

A number of analysts recently weighed in on the company. Zacks Investment Research upgraded Proteostasis Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research note on Wednesday, November 13th. ValuEngine upgraded Proteostasis Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Proteostasis Therapeutics in a report on Friday, October 18th. Five research analysts have rated the stock with a buy rating, Proteostasis Therapeutics has a consensus rating of “Buy” and a consensus target price of $6.67.

The company has a quick ratio of 6.89, a current ratio of 6.89 and a debt-to-equity ratio of 0.18. The company’s 50 day moving average is $1.37 and its 200 day moving average is $1.01.

Proteostasis Therapeutics (NASDAQ:PTI) last issued its earnings results on Thursday, November 7th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.15. Research analysts forecast that Proteostasis Therapeutics Inc will post -1.3 EPS for the current fiscal year.

In other Proteostasis Therapeutics news, major shareholder Enterprise Associates 12 New sold 117,164 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $2.45, for a total transaction of $287,051.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 19.80% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC increased its position in Proteostasis Therapeutics by 62.4% during the third quarter. Squarepoint Ops LLC now owns 44,569 shares of the company’s stock worth $38,000 after purchasing an additional 17,120 shares during the last quarter. Paloma Partners Management Co purchased a new stake in shares of Proteostasis Therapeutics during the 2nd quarter valued at $150,000. Jane Street Group LLC increased its holdings in shares of Proteostasis Therapeutics by 445.5% during the 2nd quarter. Jane Street Group LLC now owns 175,050 shares of the company’s stock worth $171,000 after buying an additional 142,958 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Proteostasis Therapeutics in the 2nd quarter worth $178,000. Finally, A.R.T. Advisors LLC acquired a new position in Proteostasis Therapeutics in the second quarter valued at $189,000. 41.60% of the stock is owned by institutional investors.

About Proteostasis Therapeutics (NASDAQ:PTI)

Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.

Read More: Index Funds

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.